Last updated: February 20, 2026
What is NDC 00143-9501?
NDC 00143-9501 corresponds to the medication Venclexta (venetoclax), developed by AbbVie. It is a BCL-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in specific cases. Approved by the FDA in 2016, Venclexta plays a vital role in targeted oncology therapy.
Current Market Landscape
Therapeutic Area Overview
Venclexta operates in the oncology segment, with focus on hematologic malignancies. The global hematological cancer drug market was valued at approximately USD 13.2 billion in 2022, with an expected CAGR of 8.2% from 2023 to 2030 (Grand View Research, 2022).
Competitive Positioning
Venclexta's primary competitors include:
- Ibrutinib (Imbruvica, AbbVie/Johnson & Johnson)
- Acalabrutinib (Calquence, AstraZeneca)
- Obinutuzumab (Gazyva, Genentech)
Market share dynamics favor Venclexta due to targeted mechanisms, combination efficacy, and expanding indications.
Prescription Trends
- U.S. prescriptions increased by approximately 30% annually between 2018 and 2022.
- The drug is prescribed mainly in hematologic oncology settings, with growing use in first-line therapy in combination regimens.
- Approvals for AML in 2020 broaden its application scope, contributing to further growth.
Price History and Pricing Structure
Listed Price
- The wholesale acquisition cost (WAC) for Venclexta is roughly USD 11,400 per month for most indications.
- Price varies based on dosage, treatment regimen, and negotiated discounts with payers.
Pricing Compared to Market
| Drug |
Indication |
Approximate WAC per month |
Notes |
| Venclexta |
CLL, AML, SLL |
USD 11,400 |
Standard dosing, varies with regimen |
| Ibrutinib |
CLL, MCL, Waldenström’s macroglobulinemia |
USD 12,500 |
Slightly higher, multi-indication |
| Acalabrutinib |
CLL, SLL |
USD 10,800 |
Similar market segment |
Price Trends
From 2016 to 2022, the price remained relatively stable, with slight increases (~2-3% annually). Post-expansion of indications, price adjustments may occur to reflect new usage scenarios.
Market Projections
Revenue Forecasts
- Current sales are estimated at USD 1.2 billion in 2022, driven predominantly by the U.S. market.
- Global sales are projected to reach USD 2.3 billion by 2025, with compounded annual growth rate (CAGR) of 20%, influenced by:
- Expanded indications in AML
- Adoption in combination therapies
- Emergence of biosimilars or generic competitors
Cost Drivers
- Expanding indications in AML, particularly in elderly patients, increase annual treatment costs.
- Market entry of biosimilars could pressure pricing, especially in Europe and emerging markets.
Regulatory and Policy Impact
Pricing adjustments may occur in response to payers' negotiation power, especially following formulary assessments and outcome-based pricing models.
Key Market Drivers and Risks
Drivers:
- Accelerated approval for AML expands target patient pool.
- Growing demand for targeted therapies in hematologic cancers.
- Payer willingness to reimburse for superior outcomes.
Risks:
- Potential biosimilar/proprietary competitors reducing prices.
- Regulatory restrictions on pricing, especially in markets outside the U.S.
- Cost containment measures affecting growth.
Summary of Price Projections
| Year |
Estimated WAC per month |
Variability Factors |
Source of Adjustment |
| 2023 |
USD 11,400 |
Market stability, indication expansion |
Payer negotiations, inflation adjustment |
| 2024 |
USD 11,700 |
Increased adoption, biosimilar risks |
New indication approvals |
| 2025 |
USD 12,000 |
Market maturity, price competition |
Biosimilar entry, policy changes |
Key Takeaways
- NDC 00143-9501 (Venclexta) holds a significant position within hematology-oncology, with sustained growth driven by expanded indications and evolving treatment protocols.
- Current pricing is stable but subject to upward adjustments from indication expansion and potential biosimilar competition.
- Global sales are projected to increase significantly, with revenue growth stabilized by price controls and patent protections.
FAQs
1. What factors influence Venclexta’s pricing?
Pricing depends on indications, dosage regimens, payer negotiations, and competition from biosimilars or generics.
2. How does Venclexta's market share compare to competitors?
It holds a leading position in CLL and SLL indications, with expanding AML use improving its market footprint.
3. What impact will biosimilars have on future prices?
Biosimilars could exert downward pricing pressure, especially outside the U.S., but patent exclusivity prevents immediate competition.
4. Are there upcoming indications that will affect its market size?
Yes, further approvals in AML and potential combination therapies are expected to expand its patient population.
5. How do government policies affect Venclexta’s pricing?
Reimbursement policies, value-based pricing initiatives, and formulary decisions can influence net prices.
References
[1] Grand View Research. (2022). Hematology and Oncology Drug Market Size, Share & Trends Analysis Report.
[2] FDA. (2016). Venclexta (venetoclax) Approval.
[3] IQVIA. (2022). Prescription Dynamics in Oncology.
[4] Evaluate Pharma. (2022). Oncology Market Forecasts.
